Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia | Zendy

H. Foo | Zendy; Michel Sebba Chater | Zendy; Michael Maley | Zendy; Sebastiaan J. van Hal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia

Author(s) -

H. Foo,

Michel Sebba Chater,

Michael Maley,

Sebastiaan J. van Hal

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku107

Subject(s) - medicine , glycopeptide , antimicrobial , enterococcus faecalis , enterococcus , bacteremia , retrospective cohort study , antibiotics , surgery , microbiology and biotechnology , staphylococcus aureus , biology , bacteria , genetics

Enterococci are an important cause of nosocomial and community-acquired infections, with bacteraemia being one of the most common presentations. Although inappropriate antimicrobial therapy has been associated with poorer outcomes in Enterococcus faecalis (EF) bacteraemia, the impact of antimicrobial choice, namely β-lactam versus glycopeptide therapy, has not been well described. We sought to determine whether choice of antibiotic affects patient outcomes in EF bacteraemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research